Navigation Links
Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
Date:9/15/2011

TARRYTOWN, N.Y., Sept. 15, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #2 employer in the global biopharmaceutical industry in its annual survey of Top Employers.

"It is extremely satisfying for Regeneron to be recognized by Science as one of the best  places to be a scientist," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "It is a priority at Regeneron to create an environment where talented individuals can conduct groundbreaking science and where creativity and innovation are encouraged and recognized.  We are grateful to Science for acknowledging our science-based culture and to our fantastic employees who give their best every day to the pursuit of important new medicines through scientific discoveries."

Details of the rankings and survey results will be published online on Sept. 16 at www.sciencecareers.org/TopEmployers2011 and will be included in the Oct. 7 print issue of Science.

Regeneron, founded in 1988, currently has approximately 1,670 employees, of whom more than 300 hold Ph.D. or M.D. degrees.  Regeneron has added about 1,000 employees since 2007, primarily to support its research and development programs.  The Company proprietary VelociGene® and VelocImmune® technologies were used to discover and develop eight fully-human monoclonal antibodies that are in clinical development.  The Company's Trap fusion protein technology was applied to develop ARCALYST® (rilonacept) and two product candidates that have completed Phase 3 clinical studies.

About the Top Employers SurveyThe Science and Science Careers' annual Top Employers Survey polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the driving characteristics of the best employers and to identify the 20 best employers from a universe of about 200 companies.  Respondents to the web-based survey were asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change, and a research-driven environment.

According to Science, the 2011 global survey results were based on 3,784 responses from North America (80%), Europe (12%), and Asia/Pacific Rim (6%).  A mathematical process was used to assign a unique score to rate each company's employer reputation.

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on www.regeneron.com.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
2. Regeneron Reports Second Quarter 2011 Financial and Operating Results
3. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
4. Trading in Regeneron Common Stock Halted
5. Regeneron Reports First Quarter 2011 Financial and Operating Results
6. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
9. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
10. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
11. Regeneron Announces March 2011 Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):